HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Sept. 22, 2022 (HealthDay News) -- Atopic dermatitis (AD) severity and time spent managing symptoms have the strongest associations with self-reported disease burden, according to a study recently published in JAMA Dermatology.
Rawaan Elsawi, from University of Toronto and Women's College Research Institute, and colleagues examined the burden of AD among 1,065 adult survey respondents (83 percent women).
The researchers found that 46 percent of participants reported low-moderate AD impact scores (2 to 3), while 51 percent reported high-significant impact scores (4 to 5) and just 3 percent reported no disease burden (impact score, 1). Overall impact scores were strongly associated with current AD severity (odds ratios, 4.13 and 13.63 for moderate and severe, respectively, versus mild) and time spent managing AD (odds ratios, 2.67 and 5.34 for 11 to 20 hours and ≥21 hours, respectively, versus less than five hours).
"In this survey study, skin disease severity and time spent managing symptoms were strongly associated with AD disease burden. No single aspect of the disease seemed to drive disease burden; rather, the burden is multidimensional and heterogeneous," the authors write. "Further work to address the complex burden of AD, including strategies to reduce time spent managing AD, and understanding the fullness of the patient experience is needed."
Several authors disclosed financial ties to the pharmaceutical industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Published on September 22, 2022